KALA BIO (KALA) Competitors $18.62 +1.62 (+9.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$18.88 +0.25 (+1.37%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. KMDA, MBX, CGEM, NBTX, AURA, INBX, ADCT, PRTC, YMAB, and VIGLShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Kamada (KMDA), MBX Biosciences (MBX), Cullinan Therapeutics (CGEM), Nanobiotix (NBTX), Aura Biosciences (AURA), Inhibrx Biosciences (INBX), ADC Therapeutics (ADCT), PureTech Health (PRTC), Y-mAbs Therapeutics (YMAB), and Vigil Neuroscience (VIGL). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Its Competitors Kamada MBX Biosciences Cullinan Therapeutics Nanobiotix Aura Biosciences Inhibrx Biosciences ADC Therapeutics PureTech Health Y-mAbs Therapeutics Vigil Neuroscience Kamada (NASDAQ:KMDA) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk. Does the media prefer KMDA or KALA? In the previous week, KALA BIO had 6 more articles in the media than Kamada. MarketBeat recorded 9 mentions for KALA BIO and 3 mentions for Kamada. Kamada's average media sentiment score of 1.61 beat KALA BIO's score of 0.79 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive KALA BIO 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, KMDA or KALA? Kamada has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$169.52M2.38$14.46M$0.3420.65KALA BIO$3.89M33.60-$38.51M-$6.79-2.74 Is KMDA or KALA more profitable? Kamada has a net margin of 11.22% compared to KALA BIO's net margin of 0.00%. Kamada's return on equity of 7.41% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Kamada11.22% 7.41% 5.18% KALA BIO N/A -686.43%-76.81% Do institutionals and insiders hold more shares of KMDA or KALA? 20.4% of Kamada shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 8.3% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, KMDA or KALA? Kamada has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.82, meaning that its stock price is 282% less volatile than the S&P 500. Do analysts prefer KMDA or KALA? Kamada presently has a consensus price target of $13.00, suggesting a potential upside of 85.19%. KALA BIO has a consensus price target of $21.75, suggesting a potential upside of 16.81%. Given Kamada's higher probable upside, equities analysts plainly believe Kamada is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67KALA BIO 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryKamada beats KALA BIO on 11 of the 17 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$130.71M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-2.7421.5775.5726.02Price / Sales33.60254.90461.9291.11Price / CashN/A44.4425.8129.91Price / Book9.229.6112.526.25Net Income-$38.51M-$53.29M$3.29B$270.76M7 Day Performance28.59%0.57%0.78%2.54%1 Month Performance123.80%4.56%4.56%5.73%1 Year Performance215.06%10.44%66.82%25.85% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.8969 of 5 stars$18.62+9.5%$21.75+16.8%+215.1%$130.71M$3.89M-2.7430High Trading VolumeKMDAKamada4.4819 of 5 stars$7.18+1.7%$13.00+81.1%+28.6%$412.92M$160.95M21.12360Positive NewsShort Interest ↓MBXMBX Biosciences0.1318 of 5 stars$12.27-5.0%N/AN/A$412.15MN/A-2.70N/ANews CoveragePositive NewsAnalyst UpgradeCGEMCullinan Therapeutics2.1928 of 5 stars$6.98+1.1%$26.80+283.7%-63.6%$411.72MN/A-2.1630Analyst ForecastNBTXNanobiotix0.641 of 5 stars$8.54+0.3%$8.00-6.4%+96.0%$409.60M$39.18M0.00100News CoverageUpcoming EarningsShort Interest ↑Gap UpAURAAura Biosciences2.2339 of 5 stars$6.49+1.1%$22.00+239.0%-38.6%$405.21MN/A-3.3350Positive NewsINBXInhibrx Biosciences1.0648 of 5 stars$27.83+0.4%N/A+67.7%$402.98M$200K-2.63166Positive NewsADCTADC Therapeutics3.0264 of 5 stars$3.51+3.1%$7.75+121.1%+6.8%$395.44M$70.84M-2.24310PRTCPureTech Health0.5539 of 5 stars$16.34+3.0%$45.00+175.5%-19.5%$394.16M$4.83M0.00100Short Interest ↑YMABY-mAbs Therapeutics1.9254 of 5 stars$8.58+0.1%$9.62+12.2%-37.5%$389.65M$87.68M-17.15150Positive NewsVIGLVigil NeuroscienceN/A$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340 Related Companies and Tools Related Companies Kamada Competitors MBX Biosciences Competitors Cullinan Therapeutics Competitors Nanobiotix Competitors Aura Biosciences Competitors Inhibrx Biosciences Competitors ADC Therapeutics Competitors PureTech Health Competitors Y-mAbs Therapeutics Competitors Vigil Neuroscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
